Prognostic factors in chronic myeloid leukemia (CML)

Onkologie

Volumn 31, Issue 11, 2008, Pages 576-578

  Hochhaus, Andreas ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; ALPHA INTERFERON; BCR ABL PROTEIN; BREAKPOINT CLUSTER REGION PROTEIN; HYDROXYUREA; IMATINIB; INTERFERON; PROTEIN TYROSINE KINASE;

CANCER SURVIVAL; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CHROMOSOME MUTATION; CHROMOSOME TRANSLOCATION 22; CHROMOSOME TRANSLOCATION 9; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; EDITORIAL; ENZYME ACTIVITY; GENETIC POLYMORPHISM; GENOMICS; HUMAN; LEUKEMOGENESIS; PROGNOSIS; SCORING SYSTEM; TREATMENT RESPONSE;

CHROMOSOMES, HUMAN, PAIR 9; FEMALE; GENE DELETION; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; HYDROXYUREA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 58849151347     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000163070     Document Type: Editorial

References (30)

1. Hasford J, Pfirrmann M, Hehlmann R, et al. for the Collaborative CML Prognostic Factors Project Group: A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst 1998;90:850-858.
2. Sokal JE: Prognosis in chronic myeloid leukaemia: biology of the disease vs. treatment. Baillieres Clin Haematol 1987;1:907-929.
3. Bonifazi F, de Vivo A, Rosti G, et al.: Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 2001;98:3074-3081.
4. Baccarani M, Saglio G, Goldman J, el al.: Evolving concepts in the management of chronic myeloid leukemia. Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006;108:1809-1820.
5. Hasford J, Pfirrmann M, Shepherd P, et al.: The impact of the combination of baseline risk group and cytogenetic response on the survival of patients with chronic myeloid leukemia treated with interferon alpha. Haematologica 2005;90:335-340.
6. Huntly BJP, Reid AG, Bench AJ, et al.: Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood 2001;98:1732-1738.
7. Kolomietz E, Al Maghrabi J, Brennan S, et al.: Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis. Blood 2001;97:3581-3588.
8. Popenoe DW, Schaefer-Rego K, Mears JG, Bank A, Leibowitz D: Frequent and extensive deletion during the 9.22 translocation in CML. Blood 1986;68:1123-1128.
9. Grand F, Kulkarni S, Chase A, et al.: Frequent deletion of hSNF5/INI1, a component of the SWI/SNF complex, in chronic myeloid leukemia. Cancer Res 1999;59:3870-3874.
10. Sinclair PB, Nacheva EP, Leversha M, et al.: Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood 2000;95:738-743.
11. Yoong Y, VanDeWalker TJ, Carlson RO, Dewald GW, Tefferi A: Clinical correlates of submicroscopic deletions involving the ABL-BCR translocation region in chronic myeloid leukemia. Eur J Haematol 2005;74:124-127.
12. Kreil S, Waghorn K, Pfirrmann M, et al.: Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia. Blood 2007;110:1283-1290.
13. Huntly BJP, Bench AJ, Delabesse E, et al.: Derivative chromosome 9 deletions in chronic myeloid leukemia: poor prognosis is not associated with loss of ABL-BCR expression, elevated BCR-ABL levels, or karyotypic instability. Blood 2002;99:4547-4553.
14. Melo JV, Hochhaus A, Yan XH, Goldman JM: Lack of correlation between ABL-BCR expression and response to interferon-alpha in chronic myeloid leukaemia. Br J Haematol 1996;92:684-686.
15. Fourouclas N, Campbell PJ, Bench AJ, et al.: Size matters: the prognostic implications of large and small deletions of the derivative 9 chromosome in chronic myeloid leukemia. Haematologica 2006;91:952-955.
16. Li JY, Xu W, Wu W, et al.: The negative prognostic impact of derivative 9 deletions in patients who received hydroxyurea treatment for chronic myelogenous leukemia in chronic phase. Onkologie 2008;585-589.
17. Huntly BJP, Guilhot F, Reid AG, et al.: Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions. Blood 2003;102:2205-2212.
18. Quintas-Cardama A, Kantarjian H, Talpaz M, et al.: Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood 2005;105:2281-2286.
19. Hughes TP, Kaeda J, Branford S, et al.: Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003;349:1421-1432.
20. Tipping AJ, Deininger MW, Goldman JM, et al.: Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate. Exp Hematol. 2003;31:1073-1080.
21. McLean LA, Gathmann I, Capdeville R, et al.: Pharmacogenomic analysis of cytogenetic response in chronic myeloid leukemia patients treated with imatinib. Clin Cancer Res 2004;10:155-165.
22. Crossman Lc, Mori M, Hsieh YC, et al.: In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures. Haematologica 2005;90:459-464.
23. Yong AS, Szydlo RM, Goldman JM et al.: Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML. Blood 2006;107:205-212.
24. Dressman MA, Malinowski R, McLean LA, et al.: Correlation of major cytogenetic response with a pharmacogenetic marker in chronic myeloid leukemia patients treated with imatinib (STI571). Clin Cancer Res 2004;10:2265-2271.
25. Cilloni D, Messa F, Gottardi E, et al.: Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation. Cancer 2004;101:979-988.
26. Schultheis B, Szydlo R, Mahon FX, et al.: Analysis of total phosphotyrosine levels in CD34+ cells from CML patients to predict the response to imatinib mesylate treatment. Blood 2005;105:4893-4894.
27. White D, Saunders V, Lyons AB, et al.: In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. Blood 2005;106:2520-2526.
28. Merx K, Müller MC, Kreil S, et al.: Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha. Leukemia 2002;16:1579-1583.
29. Wang L, Pearson K, Ferguson JE, et al.: The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia. Br J Haematol 2003;120:990-999.
30. Paschka P, Müller MC, Merx K, et al.: Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha: low levels of residual disease are associated with continuous remission. Leukemia 2003;17:1687-1694.